122 completed, 41 recruiting, 29 active not recruiting, 19 terminated. 122 Phase 2, 102 Phase 1, 18 Phase 3, 16 Not applicable, 3 Early Phase 1.
Follow Myosarcoma: new trials by email Literature Review of Myosarcoma trials Research Report on Myosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| Tumor-Lymph Node Mapping ICG (Indocyanine Green) - Pediatric Solid Tumors, Rhabdomyosarcoma | Not yet recruiting | University of Rochester | 10 | 2026-12-13 | 2026-08-26 | |
| my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults my.naviGATE Digital Tool - Sarcoma, Osteosarcoma | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 143 | 2026-08-20 | 2026-04-08 |
| Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma Proton Therapy (Adaptive) - Pediatric Solid Tumors, Rhabdomyosarcoma | Not applicable | Recruiting | St. Jude Children's Research Hospital | 100 | 2026-08-20 | 2026-08-21 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy, Left Arm treated with vehicle serum and Intense Pulsed Light Therapy - Photodamaged Skin | Phase 2 / Phase 3 | Not yet recruiting | Goldman, Butterwick, Fitzpatrick and Groff | 20 | 2026-07-10 | 2026-07-07 |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Becotatug Vedotin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma | Phase 1 | Recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-13 |
| Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma | Early Phase 1 | Recruiting | University of California, Irvine | 25 | 2026-05-01 | 2026-07-31 |
| Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors SC-CAR.GPC3xIL15.21 CAR T cells - Solid Tumor (Excluding CNS), Hepatocellular Carcinoma | Phase 1 | Not yet recruiting | Seattle Children's Hospital | 21 | 2026-04-01 | 2025-11-04 |
| Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib - Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2026-03-01 | 2026-03-03 |
| Radiological Diagnosis of Pediatric Neck Swellings Lipoma, Branchial Cleft Anomalies | Active not recruiting | Sohag University | 50 | 2026-02-20 | 2026-07-30 | |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells - Rhabdomyosarcoma, Ewing Sarcoma | Phase 1 | Recruiting | Children's National Research Institute | 18 | 2026-01-27 | 2026-08-13 |
| A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma ATRA+VAC, ATRA+VAC+Anlotinib - Rhabdomyosarcoma | Phase 2 | Not yet recruiting | Fudan University | 106 | 2026-01-01 | 2026-01-21 |
| Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells SC-CAR.GPC3xIL15.21 CAR T cells - Solid Tumor (Excluding CNS), Liver Cell Carcinoma | Phase 1 | Recruiting | Seattle Children's Hospital | 21 | 2025-12-22 | 2026-02-17 |
| Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors Lutetium Lu 177-Edotreotide, Amino Acid Solution - Somatostatin Receptor Positive, NETs | Phase 1 | Recruiting | ITM Solucin GmbH | 20 | 2025-09-26 | 2026-09-25 |
| FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma fludarabine, cyclophosphamide, cetuximab - Rhabdomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 50 | 2025-09-22 | 2026-10-16 |
| Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells 21.15.GPC3-CAR T cells - Hepatoblastoma, Hepatocellular Carcinoma | Phase 1 | Recruiting | Baylor College of Medicine | 21 | 2025-06-10 | 2025-11-03 |
| Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma mRNA Tumor Vaccine Therapy - Rhabdomyosarcoma | Early Phase 1 | Not yet recruiting | Xinxin Zhang | 5 | 2025-05-01 | 2025-04-22 |
| Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma Consolidative radiation therapy (cRT) - Metastatic Sarcoma, Radiation Therapy Patient | Not applicable | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 70 | 2025-03-25 | 2026-07-13 |
Showing 20 of 248. Sign in to see all of them.
Rhabdomyosarcoma (230) · Sarcoma (127) · Sarcoma, Ewing (109) · Osteosarcoma (95) · Neuroblastoma (93) · Wilms Tumor (60) · Medulloblastoma (41) · Rhabdoid Tumor (40) · Sarcoma, Synovial (40) · Liposarcoma (37) · Neuroectodermal Tumors, Primitive, Peripheral (36) · Hepatoblastoma (35) · Neurofibrosarcoma (32) · Leiomyosarcoma (30) · Fibrosarcoma (27)
Neoplasms by Histologic Type (248) · Neoplasms, Muscle Tissue (248) · Neoplasms, Connective and Soft Tissue (246) · Neoplasms (223) · Neoplasms, Connective Tissue (162) · Neoplasms, Nerve Tissue (143) · Neoplasms, Bone Tissue (133) · Neoplasms, Glandular and Epithelial (125) · Sarcoma (121) · Neuroectodermal Tumors (118) · Neoplasms by Site (115) · Neoplasms, Germ Cell and Embryonal (114) · Neoplasms, Neuroepithelial (111) · Neuroectodermal Tumors, Primitive (102)
Cyclophosphamide (26) · Vincristine (26) · Irinotecan (21) · Temozolomide (18) · Doxorubicin (16) · Radiotherapy (16) · Dactinomycin (15) · Filgrastim (15) · Ifosfamide (14) · Etoposide (11) · Magnetic Resonance Spectroscopy (10) · Granulocyte Colony-Stimulating Factor (9) · Melphalan (9) · Radiation (9) · Vinorelbine (9)
National Cancer Institute (NCI) (40) · Children's Oncology Group (17) · St. Jude Children's Research Hospital (17) · European Organisation for Research and Treatment of Cancer - EORTC (12) · Baylor College of Medicine (7) · Memorial Sloan Kettering Cancer Center (6) · Emory University (5) · Eli Lilly and Company (4) · Novartis Pharmaceuticals (4) · Seattle Children's Hospital (4) · Children's National Research Institute (3) · City of Hope Medical Center (3) · Eisai Inc. (3) · Fudan University (3) · Goldman, Butterwick, Fitzpatrick and Groff (3)
United States (185) · Canada (34) · Australia (24) · France (24) · Puerto Rico (22) · Germany (20) · Spain (16) · United Kingdom (16) · Netherlands (14) · Italy (13) · Switzerland (13) · Belgium (12) · China (10) · New Zealand (10) · Denmark (9)
AeRang Kim, MD, PhD (4) · Crystal L Mackall, M.D. (3) · David Steffin, MD (3) · Robert Maki, MD, PhD (3) · Alok Kothari, M.D. (2) · Andrea Hayes-Jordan, MD (2) · Brenda Weigel, MD (2) · Christine M Heske, M.D. (2) · Holly Meany, MD (2) · Hongxia Wang, Doctor (2) · Jonathan Metts, MD (2) · Kim Kramer, MD (2) · Thomas Cash, MD (2)
PMID 31401903, PMID 38603649, PMID 31575518, PMID 42573020, PMID 10797354, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17264331, PMID 17336054, PMID 17634494, PMID 18286501, PMID 18391430, PMID 18676758, PMID 19088049, PMID 19451429, PMID 19451433, PMID 19556464, PMID 20434400, PMID 20471824, PMID 21357783, PMID 21896345, PMID 22104356, PMID 22682017, PMID 22954508, PMID 23071222, PMID 23382028, PMID 24215845, PMID 24618336, PMID 24747207, PMID 25209242, PMID 25452614, PMID 25858498, PMID 26106946, PMID 27117972, PMID 27441995, PMID 2753146, PMID 28674120, PMID 28926470, PMID 28950372, PMID 29216400, PMID 29343557, PMID 29450452
U10CA180886 (20), U10CA098543 (10), P30CA008748 (2), P30CA033572 (2), UM1CA097452 (2), UM1CA228823 (2), 2014 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), N01CM00071 (1), N01CM62203 (1), N01CM62206 (1)